Atherosclerosis is fundamentally an active, chronic immune-inflammatory disease of the vascular wall rather than passive lipid accumulation. While High-Sensitivity C-Reactive Protein (hs-CRP < 0.5 mg/L) reflects systemic downstream inflammation, advanced vascular testing utilizes Lp-PLA2 (the PLAC test) to measure enzymatic thinning of the coronary fibrous cap and Myeloperoxidase (MPO) to quantify active neutrophil-mediated oxidative damage and nitric oxide consumption.
For over a century, atherosclerosis was conceptualized as a plumbing problem: cholesterol was viewed as grease slowly accumulating inside the coronary pipes until the lumen blocked.
In modern vascular biology, immunology, and preventive cardiology, that model has been completely overturned.
Atherosclerosis is an active, chronic inflammatory immune disease of the arterial intima.
A patient can have a massive, stable calcified plaque for thirty years without incident - or a small, highly inflamed soft plaque that suddenly ruptures on a Tuesday morning, triggering fatal coronary thrombosis.
What is the biological mechanism of vascular endothelial inflammation, how does the PLAC test (Lp-PLA2) measure fibrous cap thinning inside coronary plaques, and how does Myeloperoxidase (MPO) predict acute heart attacks?
1. The Inflammatory Paradigm of Atherosclerosis#
The proof that inflammation is a distinct, causal driver of cardiovascular disease was established in the landmark CANTOS Trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) led by Dr. Paul Ridker (Harvard Medical School / NEJM 2017):
[THE CANTOS TRIAL PROOF (Ridker et al., NEJM 2017)]
- Patients with prior heart attacks and hs-CRP ≥ 2.0 mg/L were given an IL-1β inhibitor.
- Serum hs-CRP was reduced by 40% with ZERO CHANGE IN CHOLESTEROL (LDL-C unchanged).
- RESULT: Statistically significant 15% to 30% reduction in cardiovascular death and repeat MI.
- The Clinical Reality: Low cholesterol alone is insufficient if the vascular wall remains inflamed; eradicating both ApoB particles and vascular endothelial inflammation is mandatory for cardiovascular longevity.
2. The 3-Tier Vascular Inflammation Biomarker Panel#
[THE VASCULAR INFLAMMATORY CASCADE]
│
┌────────────────────────────────┼────────────────────────────────┐
▼ ▼ ▼
[1. SYSTEMIC (hs-CRP)] [2. VESSEL-WALL (Lp-PLA2)] [3. LEUKOCYTE (MPO)]
- Hepatic acute-phase. - Synthesized by plaque - Secreted by activated
- Triggered by IL-6. macrophages in cap. neutrophils & monocytes.
- Downstream marker of - Hydrolyzes oxidized lipids. - Generates HOCl (bleach).
systemic arterial stress. - THINS FIBROUS CAP (RUPTURE). - CONSUMES NITRIC OXIDE (NO).
3. High-Sensitivity C-Reactive Protein (hs-CRP)#
C-Reactive Protein is an evolutionary conserved pentraxin protein synthesized by hepatocytes under the direct stimulation of Interleukin-6 (IL-6):
| hs-CRP Concentration | Clinical Risk Stratification | Pathophysiological Interpretation |
|---|---|---|
| < 0.5 mg/L | Optimal Longevity Target | Minimal vascular endothelial activation; lowest long-term cardiovascular and all-cause mortality risk. |
| 0.5 to 1.0 mg/L | Low Risk | Standard healthy baseline. |
| 1.0 to 3.0 mg/L | Moderate Risk | Chronic low-grade sterile inflammation (driven by visceral adiposity, insulin resistance, or periodontal disease). |
| > 3.0 mg/L | High Cardiovascular Risk | High vascular inflammatory tone; warrants aggressive lifestyle and medical optimization. |
| > 10.0 mg/L | Acute Systemic Event | Typically reflects acute infection, physical trauma, or autoimmune flare (re-test in 3 to 4 weeks). |
4. Lipoprotein-Associated Phospholipase A2 (Lp-PLA2 / The PLAC Test)#
While hs-CRP measures general systemic inflammation, Lp-PLA2 is a vascular-specific enzyme synthesized directly inside the coronary plaque:
[ATHEROSCLEROTIC PLAQUE MACROPHAGES & FOAM CELLS SYNTHESIZE Lp-PLA2]
│
▼
[Lp-PLA2 CLEAVES OXIDIZED PHOSPHOLIPIDS IN THE PLAQUE FIBROUS CAP]
│
┌─────────────────────────────┴─────────────────────────────┐
▼ ▼
[LYSOPHOSPHATIDYLCHOLINE (Lyso-PC)] [OXIDIZED FREE FATTY ACIDS (ox-FFAs)]
- Chemoattractant for monocytes. - Toxic to vascular smooth muscle cells.
- Stimulates apoptosis of cap cells. - ACTIVATES MATRIX METALLOPROTEINASES.
│
▼
[ENZYMATIC DISSOLUTION OF COLLAGEN ──► THIN-CAP FIBROATHEROMA (TCFA)]
│
▼
[PLAQUE RUPTURE ──► CONTACT WITH BLOODSTREAM ──► OCCLUSIVE CORONARY THROMBOSIS]
Clinical Interpretation of the PLAC Test#
- Lp-PLA2 Activity < 200 nmol/min/mL: Indicates a stable, thick, collagenous fibrous cap with low short-term rupture vulnerability.
- Lp-PLA2 Activity ≥ 225 nmol/min/mL: Indicates active enzymatic degradation of the fibrous cap, doubling the risk of coronary events independent of LDL-C or standard risk factors.
5. Myeloperoxidase (MPO): The Leukocyte Oxidative Engine#
Myeloperoxidase is an abundant heme peroxidase enzyme stored in the azurophilic granules of neutrophils and monocytes:
[ACTIVATED NEUTROPHILS DEGRANULATE MPO INTO THE ARTERIAL INTIMA]
│
▼
[MPO REACTS WITH HYDROGEN PEROXIDE (H₂O₂) & CHLORIDE IONS]
│
▼
[GENERATES HYPOCHLOROUS ACID (HOCl - CHEMICAL BLEACH)]
│
┌──────────────────────────┼──────────────────────────┐
▼ ▼ ▼
[CONSUMES NITRIC OXIDE (NO)] [OXIDIZES APOA-I ON HDL] [CONVERTS LDL TO oxLDL]
- Endothelial dysfunction. - HDL loses reverse - Accelerated foam
- Prevents vasodilation. cholesterol transport. cell recruitment.
MPO Clinical Risk Cutoffs#
- Normal Baseline: < 470 pmol/L.
- Elevated (> 540 pmol/L): Identifies patients at acute risk of cardiovascular events over the subsequent 30 days to 6 months, reflecting an active, eroding vascular lining.
Master Vascular Inflammation Panel Comparison#
| Diagnostic Test | Primary Biological Source | What It Directly Measures | Optimal Clinical Target |
|---|---|---|---|
| hs-CRP | Liver (stimulated by IL-6). | Systemic downstream vascular inflammatory tone. | < 0.5 mg/L |
| Lp-PLA2 (PLAC Test) | Macrophages inside coronary plaque. | Enzymatic thinning and rupture vulnerability of the fibrous cap. | < 200 nmol/min/mL |
| Myeloperoxidase (MPO) | Activated neutrophils and monocytes. | Acute oxidative endothelial damage and nitric oxide consumption. | < 470 pmol/L |
In the JUPITER clinical trial, patients who achieved both LDL-C < 70 mg/dL (or ApoB < 60 mg/dL) AND hs-CRP < 1.0 mg/L experienced a 79% reduction in cardiovascular events, compared to only a 36% reduction in patients who lowered cholesterol without lowering inflammation.
To explore particle count and ApoB targets, read Apolipoprotein B (ApoB): The Definitive Cardiovascular Risk Metric.
Scientific References & Clinical Practice Guidelines#
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS Trial). N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914.
- Koenig W, Khuseyinova N, Löwel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events in a middle-aged normal population: 14-year follow-up of the MONICA/KORA Augsburg Cohort Study. Circulation. 2004;110(14):1903-1908. doi:10.1161/01.CIR.0000143144.97544.7B.
- Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res. 2009;50(Suppl):S346-S351. doi:10.1194/jlr.R800086-JLR200.
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER Trial). N Engl J Med. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646.
- Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-325. doi:10.1038/nature10146.
Track Your Vascular Inflammation Panels with Meridian#
Monitoring your laboratory blood biomarkers over time gives you objective validation that your diet, exercise, and lifestyle habits are keeping your metabolic health and glucose tolerance in optimal ranges.
Meridian is an offline personal health vault for iPhone designed to give you complete ownership of your medical diagnostic data.
- Instant Lab Report Extraction: Take a photo or upload a PDF of your Vascular Inflammation Panels (hs-CRP, Lp-PLA2 Activity, Myeloperoxidase MPO, and ApoB) from Quest (Cardio IQ), Labcorp, or your clinic. Meridian extracts all biomarkers on-device using Apple VisionKit.
- Longitudinal Endothelial Tracking: Track your vascular inflammatory trends and statin/anti-inflammatory response over years with complete privacy.
- 100% On-Device & Private: Protected by hardware AES-256 encryption and FaceID. Zero cloud servers. Zero data tracking.
Take control of your vascular longevity and medical privacy today. Download Meridian on the App Store and keep your diagnostic records organized, private, and secure.